Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibroblast growth factor 1 - Venturis Therapeutics

Next Previous
X
Search
Drug Profile

Fibroblast growth factor 1 - Venturis Therapeutics

Alternative Names: Acidic FGF; Cardio Vascu-Grow; CVBT 141P ; CVBT 141S; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141ED ; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141); VT-141D; VT-141ED; VT-141P; VT-141S

Latest Information Update: 13 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CardioVascular BioTherapeutics Inc
  • Developer Venturis Therapeutics
  • Class Anti-ischaemics; Antidementias; Antidepressants; Antiparkinsonians; Antiulcers; Fibroblast growth factors; Foot disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary artery disease; Diabetic foot ulcer; Wounds
  • Phase I Peripheral arterial disorders
  • Preclinical Erectile dysfunction; Intervertebral disc degeneration; Parkinson's disease; Stroke
  • Discontinued Back pain; Diabetes mellitus; Ischaemia; Osteoporosis

Most Recent Events

  • 13 Apr 2023 Preclinical development is still ongoing for Stroke (Venturis Therapeutics pipeline, April 2023)
  • 28 May 2022 No recent reports of development identified for preclinical development in Stroke in USA
  • 05 Oct 2020 Phase-I clinical trials in Peripheral arterial disorders in USA (IM) (Venturis Therapeutics pipeline, October 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top